<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001099.pub2" GROUP_ID="PVD" ID="677999080512564005" MERGED_FROM="" MODIFIED="2013-12-18 09:26:28 +0000" MODIFIED_BY="Cathryn Broderick" REVIEW_NO="323" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2013-12-18 09:26:28 +0000" MODIFIED_BY="Cathryn Broderick">
<TITLE>Fibrinolytic agents for peripheral arterial occlusion</TITLE>
<CONTACT MODIFIED="2013-12-18 09:26:28 +0000" MODIFIED_BY="Cathryn Broderick"><PERSON ID="15787" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Iain</FIRST_NAME><LAST_NAME>Robertson</LAST_NAME><POSITION>Consultant Vascular Radiologist</POSITION><EMAIL_1>itsiainhi@gmail.com</EMAIL_1><EMAIL_2>Iain.Robertson2@ggc.scot.nhs.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Radiology</DEPARTMENT><ORGANISATION>Gartnavel General Hospital</ORGANISATION><ADDRESS_1>1053 Great Western Road</ADDRESS_1><CITY>Glasgow</CITY><ZIP>G12 0XN</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0) 141 211 3118</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-12-18 09:26:28 +0000" MODIFIED_BY="Cathryn Broderick"><PERSON ID="15787" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Iain</FIRST_NAME><LAST_NAME>Robertson</LAST_NAME><POSITION>Consultant Vascular Radiologist</POSITION><EMAIL_1>itsiainhi@gmail.com</EMAIL_1><EMAIL_2>Iain.Robertson2@ggc.scot.nhs.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Radiology</DEPARTMENT><ORGANISATION>Gartnavel General Hospital</ORGANISATION><ADDRESS_1>1053 Great Western Road</ADDRESS_1><CITY>Glasgow</CITY><ZIP>G12 0XN</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0) 141 211 3118</PHONE_1></ADDRESS></PERSON><PERSON ID="15757" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Kessel</LAST_NAME><POSITION>Consultant Vascular Radiologist</POSITION><EMAIL_1>david@kessels.co.uk</EMAIL_1><EMAIL_2>david.kessel@leedsth.nhs.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Clinical Radiology</DEPARTMENT><ORGANISATION>Leeds Teaching Hospitals Trust</ORGANISATION><ADDRESS_1>Beckett Street</ADDRESS_1><CITY>Leeds</CITY><ZIP>LS9 7TS</ZIP><REGION>West Yorkshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>44 133 206 4047</PHONE_1><PHONE_2>44 133 206 5596</PHONE_2><FAX_1>44 133 206 4691</FAX_1></ADDRESS></PERSON><PERSON ID="7187" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Berridge</LAST_NAME><SUFFIX>DM FRCSEd FRCS</SUFFIX><POSITION>Interim Medical Director</POSITION><EMAIL_1>david.berridge@leedsth.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Leeds Vascular Institute</DEPARTMENT><ORGANISATION>Leeds General Infirmary</ORGANISATION><ADDRESS_1>Great George Street</ADDRESS_1><CITY>Leeds</CITY><ZIP>LS1 3 EX</ZIP><REGION>Yorkshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 113 2064016</PHONE_1><PHONE_2>+44 113 2433144 ext: 65416</PHONE_2><FAX_1>+44 113 2460098</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-10-10 11:26:23 +0100" MODIFIED_BY="Cathryn Broderick">
<UP_TO_DATE>
<DATE DAY="21" MONTH="3" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="3" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="21" MONTH="3" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2013-12-18 08:59:56 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-12-18 08:59:56 +0000" MODIFIED_BY="Cathryn  A Broderick">
<DATE DAY="10" MONTH="10" YEAR="2013"/>
<DESCRIPTION>
<P>Searches re-run. No new included studies and one additional excluded study were identified. No change to conclusions. Minor edits made.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-10-10 11:28:12 +0100" MODIFIED_BY="Cathryn  A Broderick">
<DATE DAY="10" MONTH="10" YEAR="2013"/>
<DESCRIPTION>
<P>Searches re-run. No new included studies and one additional excluded study were identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-02-03 14:13:07 +0000" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT MODIFIED="2013-12-11 10:38:55 +0000" MODIFIED_BY="Cathryn  A Broderick">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2013-12-11 10:38:55 +0000" MODIFIED_BY="Cathryn  A Broderick">
<SOURCE MODIFIED="2013-12-11 10:38:55 +0000" MODIFIED_BY="Cathryn  A Broderick">
<NAME>Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The PVD Group editorial base is supported by the Chief Scientist Office.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-12-18 09:07:37 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-12-21 09:28:44 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-12-18 12:54:05 +0000" MODIFIED_BY="[Empty name]">Drugs to break down blood clots for people with sudden onset peripheral arterial occlusion</TITLE>
<SUMMARY_BODY MODIFIED="2009-12-21 09:28:44 +0000" MODIFIED_BY="[Empty name]">
<P>Acute reduction in blood flow to a limb can be caused by a blood clot blocking an artery or a vascular graft. If not treated promptly this condition, known as peripheral arterial occlusion, can result in amputation or be life threatening. Infusion of clot-busting drugs can restore blood flow by dissolving the clot (thrombolysis). This review found some evidence from five randomized controlled trials, involving a total of 687 patients that suggested local infusion of a drug into the affected artery is more effective than infusion into a vein, and is also associated with a lower risk of unwanted bleeding. No particular drug was more effective in preventing limb loss or death than another. The drugs investigated were streptokinase, urokinase, recombinant tissue plasminogen activator and pro-urokinase. More research is needed to confirm these findings. All of the findings of this review came from small studies that involved people with peripheral arterial ischaemia of differing severity.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-12-11 11:00:02 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-10-29 13:00:33 +0000" MODIFIED_BY="[Empty name]">
<P>Peripheral arterial thrombolysis is used in the management of peripheral arterial ischaemia. Streptokinase was originally used but safety concerns led to a search for other agents. Urokinase and recombinant tissue plasminogen activator (rt-PA) have increasingly become established as first line agents for peripheral arterial thrombolysis. Potential advantages of these agents include improved safety, greater efficacy and a more rapid response. Recently drugs such as pro-urokinase, recombinant staphylokinase and alfimperase have been introduced. This is an update of a review first published in 2010.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-11-29 02:43:30 +0000" MODIFIED_BY="[Empty name]">
<P>To determine which fibrinolytic agents are most effective in peripheral arterial ischaemia.<BR/>
</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-09-25 08:32:27 +0100" MODIFIED_BY="[Empty name]">
<P>For this update<I> </I>the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) searched the Specialised Register (last searched March 2013) and CENTRAL (2013, Issue 3) for randomised controlled trials (RCTs) comparing fibrinolytic agents to treat peripheral arterial ischaemia.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-12-21 10:22:29 +0000" MODIFIED_BY="[Empty name]">
<P>RCTs comparing fibrinolytic agents to treat peripheral arterial occlusion.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-12-21 10:22:08 +0000" MODIFIED_BY="[Empty name]">
<P>Data were analysed for the outcomes vessel patency, time to lysis, limb salvage, amputation, death, complications including major haemorrhage, stroke, and distal embolization.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-12-11 11:00:02 +0000" MODIFIED_BY="[Empty name]">
<P>Five RCTs involving a total of 687 participants with a range of clinical indications were included. No new studies were included in this update. In one three-pronged study, vessel patency was greater with intra-arterial recombinant tissue plasminogen activator (rt-PA) than with intra-arterial streptokinase (P &lt; 0.04) or intravenous rt-PA (P &lt; 0.01). In participants with peripheral arterial occlusion there was no statistically significant difference in limb salvage at 30 days with either urokinase or rt-PA, though this may reflect the small numbers in the studies. Incidences of haemorrhagic complications varied with fibrinolytic regime but there was no statistically significant difference between intra-arterial urokinase and intra-arterial rt-PA. In the three-pronged study intravenous rt-PA and intra-arterial streptokinase were associated with a significantly higher risk of haemorrhagic complications than with intra-arterial rt-PA (P &lt; 0.05).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-12-21 10:21:29 +0000" MODIFIED_BY="[Empty name]">
<P>There is some evidence to suggest that intra-arterial rt-PA is more effective than intra-arterial streptokinase or intravenous rt-PA in improving vessel patency in people with peripheral arterial occlusion. There was no evidence that rt-PA was more effective than urokinase for patients with peripheral arterial occlusion and some evidence that initial lysis may be more rapid with rt-PA, depending on the regime. Incidences of haemorrhagic complications were not statistically significantly greater with rt-PA than with other regimes. However, all of the findings come from small studies and a general paucity of results means that it is not possible to draw clear conclusions.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-12-18 09:07:37 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-12-11 11:00:07 +0000" MODIFIED_BY="[Empty name]">
<P>Peripheral arterial thrombolysis is the process of using fibrinolytic drugs to dissolve an occluding blood clot.<B> </B>Thrombolysis has become established as a useful tool in the management of acute peripheral arterial ischaemia. It is particularly useful for those cases of less than two weeks duration (<LINK REF="STD-STILE-1994" TYPE="STUDY">STILE 1994</LINK>). Although data from randomised controlled studies are not extensive, much has been learnt about indications, risks and benefits of thrombolysis. The initial selection of patients for thrombolysis or surgery is the subject of a separate Cochrane review (<LINK REF="REF-Berridge-2013" TYPE="REFERENCE">Berridge 2013</LINK>) ). Peripheral arterial thrombolysis was originally performed using intravenous administration of the drug. Relatively high doses were used to achieve therapeutic levels at the site of arterial occlusion (blockage). Subsequently, low dose intra-thrombus infusion became popular. This aimed to achieve higher local drug concentrations for a smaller total dose. Success rates appeared much improved and complication rates became more acceptable. In an attempt to achieve faster thrombolysis, a high dose bolus (the initial dose) and forced injection techniques such as 'pulse spray' have been utilised. Infusion techniques for peripheral arterial thrombolysis are the subject of another Cochrane review (<LINK REF="REF-Kessel-2004" TYPE="REFERENCE">Kessel 2004</LINK>). Overall, a relatively small number of thrombolytic agents have been used and compared within randomised controlled studies. More novel agents are starting to become available although the information to permit their role in clinical practice is currently very limited.</P>
<CONDITION MODIFIED="2009-11-29 03:24:16 +0000" MODIFIED_BY="[Empty name]">
<P>Acute peripheral arterial ischaemia results from an abrupt reduction in blood flow to a limb. It is usually caused by a blood clot (thrombosis) which may form in a diseased artery or a bypass graft, or travel there from a remote site via the bloodstream. Clinical manifestations vary depending on the site and length of the occlusion. Relatively minor reductions in perfusion result in calf pain during exercise (intermittent claudication). More significant ischaemia leads to pain at rest. If flow is not promptly restored, this may lead to tissue death requiring amputation. Thrombolysis is less often used for pain during exercise (intermittent claudication) as treatment carries significant risks.</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-11-29 03:54:04 +0000" MODIFIED_BY="[Empty name]">
<P>Peripheral arterial thrombolysis has become established as a useful adjunct to the management of peripheral arterial ischaemia and has been most useful for those cases of more recent onset, particularly within two weeks (<LINK REF="STD-STILE-1994" TYPE="STUDY">STILE 1994</LINK>). A number of fibrinolytic agents have been used for peripheral arterial thrombolysis. Streptokinase was the first agent described. Concern that repeated exposure led to significant antigenic reactions (immune responses) including anaphylaxis (a severe allergic reaction) has driven the search for alternative drugs. Urokinase (used in the USA) and rt-PA (used in the UK) have increasingly become established as the first line agents for peripheral arterial thrombolysis. Potential advantages of these agents include improved safety, greater efficacy and more rapid response. More recently, drugs such as pro-urokinase and recombinant staphylokinase have been introduced.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2009-11-29 03:55:19 +0000" MODIFIED_BY="[Empty name]">
<P>There is a considerable amount of literature on a wide variety of thrombolytic techniques and agents; however data from randomised trials are very limited. Relatively few trials have specifically considered the optimal agent for peripheral thrombolysis. Determination of the optimal agent is made more difficult because of variations in drug administration techniques as well as the drugs administered. The combination of available results, where appropriate, may allow clearer conclusions to be developed.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-11-29 03:58:59 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Primary objective</HEADING>
<P>To determine which is the most effective fibrinolytic agent for peripheral arterial thrombolysis. The logistics of the various techniques are discussed. The specific hypothesis tested was that there is no overall difference between any of the fibrinolytic agents available to the majority of patients who are suitable for peripheral arterial thrombolysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary objective</HEADING>
<P>To assess the complication rates and determine whether complication rates are higher with certain fibrinolytic agents.</P>
</SUBSECTION>
</OBJECTIVES>
<METHODS MODIFIED="2013-12-18 09:01:03 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-12-11 11:00:13 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-11-29 03:59:57 +0000" MODIFIED_BY="[Empty name]">
<P>Trials were included if participants had been randomly allocated to receive peripheral arterial thrombolysis using a fibrinolytic agent that was compared with another fibrinolytic agent.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-12-11 11:00:13 +0000" MODIFIED_BY="[Empty name]">
<P>Participants were patients requiring peripheral arterial thrombolysis in an attempt to achieve patency following a thrombo-embolic occlusion of either a native peripheral artery or a thrombosed lower limb graft. Dialysis grafts and fistulae were excluded. Participants were included irrespective of diabetic status, use of aspirin or anticoagulation post thrombolysis, or use of concurrent heparin.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-11-29 04:05:06 +0000" MODIFIED_BY="[Empty name]">
<P>All types of thrombolytic interventions, including low and high dose regimens, and all commercially available agents were considered. The focus of this review was the randomised comparison of different agents irrespective of dose and duration. It was the choice of agent and not the subsequent intervention that determined inclusion into the review.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-10-10 11:56:08 +0100" MODIFIED_BY="[Empty name]">
<P>The following outcomes were measured:</P>
<UL>
<LI>vessel patency;</LI>
<LI>time to lysis;</LI>
<LI>limb salvage;</LI>
<LI>amputation;</LI>
<LI>death;</LI>
<LI>complications, specifically risk of major haemorrhage and stroke.</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-12-18 09:01:03 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-12-18 09:01:03 +0000" MODIFIED_BY="[Empty name]">
<P>For this update<I> </I>the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) searched the Specialised Register (last searched March 2013) and the Cochrane Central Register of Controlled Trials (CENTRAL) 2013, Issue 3, part of <I>The Cochrane Library</I>, (<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used are described in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html">Specialised Register</A> section of the Cochrane Peripheral Vascular Diseases Group module in <I>The Cochrane Library</I> (<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-12-11 11:41:08 +0000" MODIFIED_BY="[Empty name]">
<P>For the original review the authors reviewed reference lists of papers found from the searches. Proceedings from the British Vascular Surgical Society, European Vascular Surgical Society, North American Society of Vascular Surgery, Society of Cardiovascular and Interventional Radiology of North America and Cardiovascular and Interventional Radiology Society of Europe meetings were also scanned for relevant trials. All major pharmaceutical firms were asked about unpublished trials that fitted the criteria described above. There were no restrictions on language.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-10-10 11:59:22 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-11-29 04:11:12 +0000" MODIFIED_BY="[Empty name]">
<P>The selection of trials for inclusion in this review was carried out independently by two of the authors. One author (IR) identified all possible trials and sent these to the second author (DCB) for consideration. Discrepancies were resolved by discussion. The criteria for selection of trials was as specified in the above section (<LINK TAG="SELECTION_CRITERIA" TYPE="SECTION">Criteria for considering studies for this review</LINK>). Eligible studies were assessed using the following criteria: randomisation technique, allocation concealment, whether the trial was double blinded and description of withdrawals and dropouts from the study. In the absence of consensus over the inclusion of a particular trial, the opinion of a third author (DK) was sought.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-11-29 04:12:28 +0000" MODIFIED_BY="[Empty name]">
<P>The following data were extracted from the available literature.</P>
<OL>
<LI>Participants: age, sex distribution.</LI>
<LI>Severity of ischaemia: Ankle Brachial Pressure Indices (ABPI), the European Consensus definition of critical ischaemia (<LINK REF="REF-Anonymous-1991" TYPE="REFERENCE">Anonymous 1991</LINK>), Fontaine classification (<LINK REF="REF-Fontaine-1954" TYPE="REFERENCE">Fontaine 1954</LINK>) and Ad Hoc Committee Recommendations (<LINK REF="REF-Anonymous-1986" TYPE="REFERENCE">Anonymous 1986</LINK>).</LI>
<LI>Outcome measures: limb salvage, vessel or graft patency, time to lysis, amputation, death and complications.</LI>
</OL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-02-10 11:09:01 +0000" MODIFIED_BY="[Empty name]">
<P>An assessment of the risk of bias in included studies was undertaken following the recommendations described in Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). This comprises a description and a judgement for each domain in a risk of bias table. Each entry addresses a specific feature of the study:</P>
<UL>
<LI>adequate sequence generation;</LI>
<LI>allocation concealment;</LI>
<LI>blinding;</LI>
<LI>incomplete outcome data addressed;</LI>
<LI>free of selective reporting;</LI>
<LI>free of other bias.</LI>
</UL>
<P>The judgement for each entry involves answering a question. Answering 'Yes' indicates low risk of bias, 'No' indicates high risk of bias, and 'Unclear' indicates either lack of information or uncertainty over the potential for bias.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-10-10 11:59:22 +0100" MODIFIED_BY="[Empty name]">
<P>For dichotomous data, odds ratios (OR) were calculated with 95% confidence intervals (CI). Individual patient data from different trials were not combined.</P>
</EFFECT_MEASURES>
<SENSITIVITY_ANALYSIS MODIFIED="2009-04-07 16:00:49 +0100" MODIFIED_BY="[Empty name]">
<P>Sensitivity analysis was not carried out as insufficient trials were identified.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-12-18 09:07:37 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-12-18 08:39:09 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> tables.</P>
<SEARCH_RESULTS MODIFIED="2013-12-11 11:00:27 +0000" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-12-11 11:00:33 +0000" MODIFIED_BY="[Empty name]">
<P>No additional studies were included in this update.</P>
<P>Five randomised controlled studies with a total of 687 patients fulfilled the inclusion criteria for consideration in this review (<LINK REF="STD-Berridge-1991" TYPE="STUDY">Berridge 1991</LINK>; <LINK REF="STD-Mahler-2001" TYPE="STUDY">Mahler 2001</LINK>; <LINK REF="STD-Meyerovitz-1990" TYPE="STUDY">Meyerovitz 1990</LINK>; <LINK REF="STD-Ouriel-1999" TYPE="STUDY">Ouriel 1999</LINK>; <LINK REF="STD-Schweizer-1996" TYPE="STUDY">Schweizer 1996</LINK>).</P>
<P>The study by Berridge et al (<LINK REF="STD-Berridge-1991" TYPE="STUDY">Berridge 1991</LINK>) compared intravenous rt-PA, intra-arterial rt-PA and intra-arterial streptokinase in a total of 60 patients. Patients were randomised into three groups of 20 patients receiving either intra-arterial rt-PA, intra-arterial streptokinase or intravenous rt-PA. It was the only trial comparing intravenous rt-PA and intra-arterial streptokinase. All patients had critical limb ischaemia of less than 30 days duration.</P>
<P>
<LINK REF="STD-Meyerovitz-1990" TYPE="STUDY">Meyerovitz 1990</LINK> described 32 patients randomised to receive either rt-PA or urokinase infusion. The clinical status of the patients was not disclosed and the majority of patients (29 out of 32) had occlusion of an infrainguinal bypass graft.</P>
<P>
<LINK REF="STD-Schweizer-1996" TYPE="STUDY">Schweizer 1996</LINK> described 120 patients randomised into two groups of 60 patients to receive either intra-arterial urokinase or intra-arterial rt-PA. Forty-nine per cent of patients within this study had Fontaine IIb classification limb ischaemia (claudication at less than 200 m) and the average length of occlusion was 6.5 cm.</P>
<P>
<LINK REF="STD-Mahler-2001" TYPE="STUDY">Mahler 2001</LINK> reported a trial of 234 patients randomised to receive rt-PA or urokinase either via a microporous balloon catheter or an end hole catheter. The majority of patients had native arterial occlusion with Fontaine stage II ischaemia (intermittent claudication).</P>
<P>The study by Ouriel (<LINK REF="STD-Ouriel-1999" TYPE="STUDY">Ouriel 1999</LINK>) reported the results of a phase II trial of 241 patients randomised to compare pro-urokinase 2 mg/hr, 4 mg/hr or 8 mg/hr with urokinase 4000 IU/min for four hours then 2000 IU/min thereafter.</P>
<P>There was considerable heterogeneity in the clinical status of the patient groups and in lesion characteristics between these studies. <LINK REF="STD-Meyerovitz-1990" TYPE="STUDY">Meyerovitz 1990</LINK> did not define clinical status, Fontaine classification or ABPI for the study population; who had 44 cm length occlusions on average. <LINK REF="STD-Berridge-1991" TYPE="STUDY">Berridge 1991</LINK> included only patients with critical limb ischaemia, with an average occlusion length of 15 cm. The larger patient group of <LINK REF="STD-Schweizer-1996" TYPE="STUDY">Schweizer 1996</LINK> included 49% of patients with Fontaine IIb claudication (walking distance of less than 200 m) and shorter occlusion lengths, mean 6.5 cm.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-12-18 08:39:09 +0000" MODIFIED_BY="[Empty name]">
<P>For this update one additional study was excluded (<LINK REF="STD-Han-2010" TYPE="STUDY">Han 2010</LINK>), making a total of eighteen excluded studies. The reasons for exclusion are documented in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-10-10 12:07:51 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for a graphical summary of methodological quality for the included studies, based on the risk of bias domains.</P>
<ALLOCATION MODIFIED="2009-11-29 04:44:55 +0000" MODIFIED_BY="[Empty name]">
<P>Five trials (<LINK REF="STD-Berridge-1991" TYPE="STUDY">Berridge 1991</LINK>; <LINK REF="STD-Mahler-2001" TYPE="STUDY">Mahler 2001</LINK>; <LINK REF="STD-Meyerovitz-1990" TYPE="STUDY">Meyerovitz 1990</LINK>; <LINK REF="STD-Ouriel-1999" TYPE="STUDY">Ouriel 1999</LINK>; <LINK REF="STD-Schweizer-1996" TYPE="STUDY">Schweizer 1996</LINK>) satisfied the inclusion criteria for adequate randomisation. Allocation concealment using sequential opaque envelopes was reported in the <LINK REF="STD-Meyerovitz-1990" TYPE="STUDY">Meyerovitz 1990</LINK> trial.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-11-29 04:46:16 +0000" MODIFIED_BY="[Empty name]">
<P>Neither patients nor observers were blinded to assignment status in the studies, with the exception of the study by <LINK REF="STD-Ouriel-1999" TYPE="STUDY">Ouriel 1999</LINK>. Differences in the volumes administered may have made this difficult. In the <LINK REF="STD-Ouriel-1999" TYPE="STUDY">Ouriel 1999</LINK> study, the treatment volumes were kept the same for the different regimes.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-10-10 12:07:51 +0100" MODIFIED_BY="[Empty name]">
<P>The study by (<LINK REF="STD-Meyerovitz-1990" TYPE="STUDY">Meyerovitz 1990</LINK>) reported by intention to treat, with exclusions clearly identified and follow up available to 30 days.</P>
<P>Berridge (<LINK REF="STD-Berridge-1991" TYPE="STUDY">Berridge 1991</LINK>) clearly described excluded patients but these were not included in the final analysis. Follow up to three months was available.</P>
<P>Schweizer (<LINK REF="STD-Schweizer-1996" TYPE="STUDY">Schweizer 1996</LINK>) appeared to have reported by intention to treat but exclusions or interruptions to therapy, if they occurred, were not clearly documented. Follow up was available to six months.</P>
<P>Ouriel (<LINK REF="STD-Ouriel-1999" TYPE="STUDY">Ouriel 1999</LINK>) clearly described treated patients but those not completing in their allocated group were excluded from the final analysis. Follow up was available to 30 days.</P>
<P>Mahler (<LINK REF="STD-Mahler-2001" TYPE="STUDY">Mahler 2001</LINK>) recorded a total for patient withdrawals at six months but did not detail reasons for withdrawal. These patients did not appear to have been included in the final analysis.</P>
</EXCLUSIONS>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-12-18 09:07:37 +0000" MODIFIED_BY="[Empty name]">
<P>The clinical heterogeneity and small patient numbers in all five studies limited their power and their likelihood of achieving a statistically significant result. The most useful method of assessing efficacy is by comparison of the most important outcome measures, which are vessel patency, time to lysis, limb salvage, amputation, death and minor and major complications. The study by Berridge (<LINK REF="STD-Berridge-1991" TYPE="STUDY">Berridge 1991</LINK>) included a comparison of intravenous rt-PA and intra-arterial streptokinase and rt-PA.</P>
<SUBSECTION>
<HEADING LEVEL="5">Intravenous rt-PA versus intra-arterial streptokinase</HEADING>
<P>(<LINK REF="STD-Berridge-1991" TYPE="STUDY">Berridge 1991</LINK>)</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<P>a) Vessel patency: assessed angiographically and graded into the three categories of complete lysis, partial lysis and failure. Intravenous rt-PA was associated with complete or partial lysis in nine of 20 patients compared with 16 of 20 patients in the intra-arterial streptokinase group (OR 4.89, 95% CI 1.20 to 19.94).</P>
<P>b)<B> </B>Limb salvage: asymptomatic limb salvage rate was reported at 30 days and 3 months. The intravenous rt-PA group achieved asymptomatic limb salvage in nine of 20 patients compared with 12 of 20 patients in the intra-arterial streptokinase group (OR 1.83, 95% CI 0.52 to 6.43).</P>
<P>c) Amputation: the amputation rate was reported at 30 days. No amputation occurred within 30 days in the intravenous rt-PA group. However, it should be noted that five patients within the intravenous rt-PA group had ongoing critical limb ischaemia at 30 days and three additional interventions had occurred including two vascular reconstructions and one intra-arterial thrombolysis. In the intra-arterial streptokinase group seven of 20 patients underwent amputation.</P>
<P>d) Death: there was no significant difference in death rates between the groups at 30 days or at three months (OR 0.30, 95% CI 0.03 to 3.15).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<P>a) Major haemorrhagic complications occurred equally in the intra-arterial streptokinase and intravenous rt-PA groups (three out of 20 patients in each group). One patient in the intravenous rt-PA group developed a cerebral haemorrhage.</P>
<P>b) Minor haemorrhagic complications (bleeding without hypotension or requirement for blood transfusion) occurred more frequently in the intravenous rt-PA group (nine patients) compared with the intra-arterial streptokinase group (three patients).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Intra-arterial streptokinase versus intra-arterial rt-PA</HEADING>
<P>(<LINK REF="STD-Berridge-1991" TYPE="STUDY">Berridge 1991</LINK>)</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<P>a) Vessel patency: assessed angiographically and graded into the three categories of complete lysis, partial lysis and failure. There was a statistically significant difference between vessel patency in the intra-arterial rt-PA (20 of 20 patients) compared with intra-arterial streptokinase (16 of 20 patients) groups (P &lt; 0.04).</P>
<P>b)<B> </B>Limb salvage: asymptomatic limb salvage rate was reported at 30 days and 3 months. The best rate of asymptomatic limb salvage was achieved with intra-arterial rt-PA (16 out of 20 patients). Intra-arterial streptokinase achieved limb salvage in 12 of 20 patients.</P>
<P>c) Amputation: the amputation rate at 30 days was lower with intra-arterial rt-PA than with intra-arterial streptokinase (P &lt; 0.05, Mann-Whitney U test).</P>
<P>d) Death: there was no significant difference in death rates between the groups at 30 days or at three months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<P>a) Major haemorrhagic complications occurred in three of 20 patients in the intra-arterial streptokinase group. No major complications occurred in the intra-arterial rt-PA group.</P>
<P>b) Minor haemorrhagic complications (bleeding without hypotension or requirement for blood transfusion) occurred more frequently with intra-arterial streptokinase (three patients) than with intra-arterial rt-PA (no patients).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Intra-arterial urokinase versus intra-arterial rt-PA</HEADING>
<P>(<LINK REF="STD-Mahler-2001" TYPE="STUDY">Mahler 2001</LINK>; <LINK REF="STD-Meyerovitz-1990" TYPE="STUDY">Meyerovitz 1990</LINK>; <LINK REF="STD-Schweizer-1996" TYPE="STUDY">Schweizer 1996</LINK>)</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<P>a) Vessel patency: <LINK REF="STD-Meyerovitz-1990" TYPE="STUDY">Meyerovitz 1990</LINK> assessed vessel patency at 4, 8 or 16 and 24 hours after the start of treatment. Angiograms were assessed by a consensus panel blinded to treatment assignation who looked for the primary endpoint of 95% or greater clot lysis. There was no statistically significant difference between urokinase and rt-PA at 24 hours. However, rt-PA was significantly more rapid at achieving lysis at 8 hours (P = 0.04).</P>
<P>The study of Schweizer et al (<LINK REF="STD-Schweizer-1996" TYPE="STUDY">Schweizer 1996</LINK>) used angiography to assess vessel patency during initial lysis treatment at non-specified time periods and by colour Doppler sonography at initial completion of lysis and at six months follow up. Thrombolysis using rt-PA was associated with statistically better vessel patency, particularly in the popliteal and calf arteries (P &lt; 0.05), both immediately after lysis and at six months follow up. Duration of treatment was shorter with rt-PA than urokinase (mean 2 hrs versus 24 hrs); however, statistical values were not recorded.</P>
<P>
<LINK REF="STD-Mahler-2001" TYPE="STUDY">Mahler 2001</LINK> assessed vessel patency at unspecified time periods during thrombolysis and by ABPI and 'oscillograms' at six months follow up. There was no statistically significant difference between rt-PA and urokinase either immediately after lysis or at six months follow up.</P>
<P>b) Limb salvage: the paper by Mahler (<LINK REF="STD-Mahler-2001" TYPE="STUDY">Mahler 2001</LINK>) did not directly record the limb salvage rate though there was a significant difference in the major amputation rate between rt-PA and urokinase. No significant difference in limb salvage for rt-PA or urokinase was seen in the studies by <LINK REF="STD-Schweizer-1996" TYPE="STUDY">Schweizer 1996</LINK> (OR 0.47, 95% CI 0.04 to 5.36) and <LINK REF="STD-Meyerovitz-1990" TYPE="STUDY">Meyerovitz 1990</LINK> (OR 0.62, 95% CI 0.09 to 4.32).</P>
<P>c) Amputation: recorded at 30 days by <LINK REF="STD-Meyerovitz-1990" TYPE="STUDY">Meyerovitz 1990</LINK> and at six months follow up in the studies of <LINK REF="STD-Schweizer-1996" TYPE="STUDY">Schweizer 1996</LINK> and <LINK REF="STD-Mahler-2001" TYPE="STUDY">Mahler 2001</LINK>.There was no statistically significant difference between the two groups in either of the trials by <LINK REF="STD-Meyerovitz-1990" TYPE="STUDY">Meyerovitz 1990</LINK> (OR 1.62, 95% CI 0.23 to 11.26) and <LINK REF="STD-Schweizer-1996" TYPE="STUDY">Schweizer 1996</LINK> (OR 2.13, 95% CI 0.19 to 24.20). <LINK REF="STD-Mahler-2001" TYPE="STUDY">Mahler 2001</LINK> demonstrated a statistically significant increase in risk of major amputation in the rt-PA group compared with the urokinase group (OR 0.29, 95% CI 0.08 to 1.06).</P>
<P>d) Death: there was no statistically significant difference between rt-PA and urokinase in any of the three trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<P>a) Major complications: no significant difference between groups was evident. In the trial of <LINK REF="STD-Meyerovitz-1990" TYPE="STUDY">Meyerovitz 1990</LINK> major haemorrhagic complications, defined as bleeding requiring surgery, transfusion of two or more units of blood or causing interruption of fibrinolytic infusion, occurred in five patients in the rt-PA group and three patients in the urokinase group (P = 0.39). <LINK REF="STD-Schweizer-1996" TYPE="STUDY">Schweizer 1996</LINK> described one case of severe gastrointestinal haemorrhage consistent with a major complication. <LINK REF="STD-Mahler-2001" TYPE="STUDY">Mahler 2001</LINK> did not demonstrate a significant difference in bleeding complications between rt-PA and urokinase. There was no statistically significant difference in risk of cerebral haemorrhage with any of the agents in these trials.</P>
<P>b) Minor complications: no significant difference between groups was found. <LINK REF="STD-Meyerovitz-1990" TYPE="STUDY">Meyerovitz 1990</LINK> described two minor bleeding episodes in the rt-PA group but none in the urokinase group. <LINK REF="STD-Schweizer-1996" TYPE="STUDY">Schweizer 1996</LINK> described five patients (8%) with groin haematomas in the urokinase group compared with nine (15%) in the rt-PA group. There was no statistically significant difference between the rt-PA and urokinase groups in the trial by <LINK REF="STD-Mahler-2001" TYPE="STUDY">Mahler 2001</LINK> (OR 0.75, 95% CI 0.12 to 4.55).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Intra-arterial pro-urokinase versus intra-arterial urokinase</HEADING>
<P>(<LINK REF="STD-Ouriel-1999" TYPE="STUDY">Ouriel 1999</LINK>)<BR/>This study was designed as a phase II randomised, double blind study with a primary endpoint of complete lysis (&gt; 95%) of the occluding thrombus. The trial was designed to assess the dose response relationship for intra-arterial pro-urokinase (r-ProUK) and compared 2 mg/hr, 4 mg/hr and 8 mg/hr pro-urokinase (r-ProUK) with intra-arterial urokinase infused at 4000 IU/min for four hours and then 2000 IU/min thereafter. Secondary endpoints were recorded including death, major amputation and bleeding complications.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcomes</HEADING>
<P>a) Vessel patency: this was assessed using angiography at eight and 24 hours and recorded using the TIMI classification (Thrombolysis in Myocardial Infarction) of Grade 0 - no lysis; grade 1- penetration but no perfusion; grade 2 - lysis to peripheral bed but slow flow; grade 3 - lysed and normal flow. There was no statistically significant difference in recanalization, defined as TIMI grade 2 or 3, at eight hours. The primary endpoint (complete lysis) increased from 39.3% in the 2 mg r-ProUK group to 56% in the 8 mg/hr r-ProUK group; 49.1% of patients in the urokinase group achieved complete lysis at eight hours.</P>
<P>b) Limb salvage: there was no statistically significant difference between any of the r-ProUK groups and urokinase.</P>
<P>c) Amputation: there was no statistically significant difference between any of the r-ProUK groups and urokinase.</P>
<P>d) Death: at 30 days the risk of mortality was 0% in the 2 mg/hr r-ProUK group versus 6.9% in the urokinase group. This was not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcomes</HEADING>
<P>a) Major haemorrhage: there was no statistically significant difference between any of the r-ProUK treatment groups and urokinase. No patient in any treatment group developed a cerebral haemorrhage.</P>
<P>b) Minor haemorrhage: minor bleeding complications did appear to follow a dose response curve in the r-ProUK group; however, there was no statistically significant difference when compared with urokinase (8 mg/hr r-ProUK 73.1% compared with urokinase 58.3%; P = 0.116).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-12-11 11:23:56 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-12-11 11:23:56 +0000" MODIFIED_BY="Cathryn  A Broderick">
<P>The available randomised trials contain different inclusion criteria, different outcome measures and relatively small numbers, which makes meaningful comparison very difficult.</P>
<P>Only one study looked at the use of intravenous rt-PA (<LINK REF="STD-Berridge-1991" TYPE="STUDY">Berridge 1991</LINK>). This treatment was statistically significantly poorer in terms of 30 day and three month asymptomatic limb salvage rates and carried a significantly higher risk of haemorrhagic complications than intra-arterial rt-PA or intra-arterial streptokinase. In the same study, intra-arterial rt-PA offered significantly greater initially successful lysis (P &lt; 0.04) and a significantly lower amputation rate than intra-arterial streptokinase. At 30 days, intra-arterial rt-PA gave a 20% increase in limb salvage over streptokinase, although this was not statistically significant.</P>
<P>Three studies compared intra-arterial urokinase to intra-arterial rt-PA. The study of <LINK REF="STD-Meyerovitz-1990" TYPE="STUDY">Meyerovitz 1990</LINK> reported that intra-arterial rt-PA tended to cause more rapid initial lysis but clinical outcomes of limb loss, death and amputation were similar in both groups. <LINK REF="STD-Schweizer-1996" TYPE="STUDY">Schweizer 1996</LINK> also demonstrated a significant reduction in treatment duration with intra-arterial rt-PA. <LINK REF="STD-Schweizer-1996" TYPE="STUDY">Schweizer 1996</LINK> found that the initial recanalization rates were greater with intra-arterial rt-PA (P &lt; 0.05) and this difference was sustained at six months. The study by <LINK REF="STD-Mahler-2001" TYPE="STUDY">Mahler 2001</LINK> was complicated by the use of two different techniques, end hole catheter versus microporous balloon infusion, in addition to urokinase and rt-PA. In the group treated by end hole catheter infusion the authors quote that rt-PA appeared to work more rapidly than urokinase, however it is difficult to extract the data from the paper that support this statement. The rates of limb loss or partial amputation were not significantly different between the groups.</P>
<P>A wide range of clinical presentations is seen within the trials reviewed, extending from patients with intermittent claudication to critical limb ischaemia; for example the study of <LINK REF="STD-Schweizer-1996" TYPE="STUDY">Schweizer 1996</LINK> included a significant proportion of patients with claudication. Thrombolysis carries with it a small risk of bleeding complications including cerebral haemorrhage. Currently, in the United Kingdom, the risk to benefit ratio of thrombolysis means that fibrinolytic agents are not frequently employed for patients with claudication. It is questionable how representative the results, for example of <LINK REF="STD-Schweizer-1996" TYPE="STUDY">Schweizer 1996</LINK>, are for a population of patients with critical limb ischaemia.</P>
<P>The incidence of haemorrhagic complications with rt-PA varies significantly between the studies and this almost certainly reflects the very different fibrinolytic regimes employed. <LINK REF="STD-Berridge-1991" TYPE="STUDY">Berridge 1991</LINK> had the most conservative rt-PA regime (intra-arterial rt-PA 0.5 mg/hr) and found a lower haemorrhagic complication rate with intra-arterial rt-PA than with either intra-arterial streptokinase or intravenous rt-PA. Notably there was no significant difference in the duration of therapy between rt-PA or streptokinase. <LINK REF="STD-Meyerovitz-1990" TYPE="STUDY">Meyerovitz 1990</LINK> used a 10 mg intrathrombic bolus followed by an infusion of 5 mg/hr. Major and minor haemorrhagic complications were more prevalent in the rt-PA group, however the difference was not statistically significant. Initial lysis was faster with rt-PA but this was not sustained at 24 hours. <LINK REF="STD-Schweizer-1996" TYPE="STUDY">Schweizer 1996</LINK> used an intrathrombic 5 mg bolus with 5 mg/hr infusion and found no major haemorrhagic complications, however 15% of rt-PA patients had large groin haematomas compared with 8% in the urokinase group. Notably, this study incorporated a post-thrombolysis anticoagulation regime with heparin (20,000 IU/24 hrs for five days).</P>
<P>In terms of more novel fibrinolytic agents, limited information from phase II and phase III trials are available. Only one study described a comparison between intra-arterial urokinase and intra-arterial pro-urokinase (<LINK REF="STD-Ouriel-1999" TYPE="STUDY">Ouriel 1999</LINK>). Pro-urokinase has improved fibrin specificity and may therefore reduce the risk of bleeding complications related to thrombolysis. This trial was a phase II study designed to determine the optimum dose regimen for intra-arterial pro-urokinase and contained several different dose regimens for pro-urokinase versus a standard dose regimen for urokinase. A dose response curve for pro-urokinase was defined but there was no statistically significant difference between the highest dose of intra-arterial prourokinase and intra-arterial urokinase in terms of vessel patency, amputation rate, deaths or complication rate.</P>
<P>Results from the phase II and phase III trials with alfimperase have now been published and include safety and efficacy data for alfimperase and surgery free survival to 30 days against placebo (<LINK REF="STD-Han-2010" TYPE="STUDY">Han 2010</LINK>). There was no significant difference on 30 day freedom from open vascular surgery between intrathrombus placebo and intrathrombus alfimperase. These trials have not been included in this review as they do not compare thrombolytic agents as described in the selection of types of studies. However, It should be noted that a significant improvement was demonstrated in the placebo group, possibly due to a mechanical effect of thrombolysis, and future studies may now need to consider a placebo control arm in any study design.</P>
<P>A number of randomised trials have compared the use of adjunctive agents such as glycoprotein IIb/IIIa receptor inhibitors with existing thrombolytic agents. Duda (<LINK REF="STD-Duda-2001" TYPE="STUDY">Duda 2001</LINK>) compared urokinase with and without abciximab and in a later trial Tepe (<LINK REF="STD-Tepe-2006" TYPE="STUDY">Tepe 2006</LINK>) compared urokinase with abciximab against rt-PA with abxicimab. These trials have not been considered to represent a comparison of thrombolytic agents and are considered within a separate review examining infusion techniques (<LINK REF="REF-Kessel-2004" TYPE="REFERENCE">Kessel 2004</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-10-10 12:09:05 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Overall, the evidence from these studies is very limited. The analysis suggests that intra-arterial rt-PA may be more effective than intra-arterial streptokinase or intravenous rt-PA but this is based on small numbers of studies. There is no evidence that intra-arterial rt-PA is more effective than intra-arterial urokinase in patients with critical limb ischaemia. Initial lysis may be more rapid with rt-PA depending on the regime. The incidence of haemorrhagic complications is not statistically significantly greater with intra-arterial rt-PA than with other equipotent regimes. The available evidence is insufficient to show any benefit in reduction of bleeding complications from the use of pro-urokinase.</P>
</APPLICABILITY_OF_FINDINGS>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-11-29 06:15:59 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-11-29 06:15:59 +0000" MODIFIED_BY="[Empty name]">
<P>The evidence is limited and consists of relatively small studies but suggests that intra-arterial rt-PA and intra-arterial urokinase may be equally effective in the treatment of critical limb ischaemia. There is less evidence in favour of intra-arterial streptokinase compared with intra-arterial rt-PA. Intravenous rt-PA appeared to be less effective than the alternative fibrinolytic agents. Complications are related to the individual fibrinolytic regime. Haemorrhagic complications tend to be more prevalent with high dose regimes of intra-arterial rt-PA and are significantly more prevalent with intravenous rt-PA. Overall, the level of evidence is such that it is not possible to draw reliable conclusions.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Future randomised trials should use accepted reporting standards and inclusion criteria. Multicentre trials will be required to definitively demonstrate any difference between rt-PA and urokinase and should include sufficient numbers to allow for clinical and lesion heterogeneity.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-11-29 06:16:59 +0000" MODIFIED_BY="[Empty name]">
<P>We would like to thank the Cochrane Peripheral Vascular Disease Group for their assistance with this review and the Cochrane Consumer Network for providing a plain language summary.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-12-21 09:54:59 +0000" MODIFIED_BY="[Empty name]">
<P>David Berridge is an author of the <LINK REF="STD-Berridge-1991" TYPE="STUDY">Berridge 1991</LINK> study which is included in the review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-12-21 09:41:54 +0000" MODIFIED_BY="[Empty name]">
<P>Iain Robertson selected the trials, wrote the text of the review, interpreted and extracted trial data, and worked on the review manuscript.</P>
<P>David C Berridge selected trials, interpreted and extracted trial data, and reviewed the manuscript.</P>
<P>David Kessel interpreted study data and reviewed the manuscript.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2013-10-10 12:13:23 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>This is the third of three reviews concerning surgical techniques for thrombolysis. </P>
<P>The first review is 'Surgery versus thrombolysis for initial management of acute limb ischaemia' (<LINK REF="REF-Berridge-2013" TYPE="REFERENCE">Berridge 2013</LINK>). The second review is 'Infusion techniques for peripheral arterial thrombolysis' (<LINK REF="REF-Kessel-2004" TYPE="REFERENCE">Kessel 2004</LINK>).</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-12-18 09:10:50 +0000" MODIFIED_BY="Heather Maxwell">
<STUDIES MODIFIED="2013-12-18 09:05:03 +0000" MODIFIED_BY="Heather Maxwell">
<INCLUDED_STUDIES MODIFIED="2013-12-11 11:18:00 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Berridge-1991" NAME="Berridge 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berridge DC, Gregson RHS, Hopkinson BR, Makin GS</AU>
<TI>Randomized trial of intra-arterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intra-arterial streptokinase in peripheral arterial thrombolysis</TI>
<SO>British Journal of Surgery</SO>
<YR>1991</YR>
<VL>78</VL>
<PG>988-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahler-2001" MODIFIED="2009-11-29 06:51:20 +0000" MODIFIED_BY="[Empty name]" NAME="Mahler 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-11-29 06:51:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mahler F, Schneider E, Hess H; Steering Committee, Study on Local Thrombolysis</AU>
<TI>Recombinant tissue plasminogen activator versus urokinase for local thrombolysis of femoropopliteal occlusions: A prospective, randomized multicenter trial</TI>
<SO>Journal of Endovascular Therapy</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>6</NO>
<PG>638-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyerovitz-1990" NAME="Meyerovitz 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meyerovitz MF, Goldhaber SZ, Reagan K, Polak JF, Kandarpa K, Grassi C et al</AU>
<TI>Recombinant tissue-type plasminogen versus urokinase in peripheral arterial and graft occlusions: A randomized trial</TI>
<SO>Radiology</SO>
<YR>1990</YR>
<VL>175</VL>
<PG>75-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ouriel-1999" NAME="Ouriel 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ouriel K, Kandarpa K, Krishna MD, Scheurr D, Hultquist M, Hodkinson G et al</AU>
<TI>Prourokinase vs urokinase for recanalization of peripheral occlusions, safety and efficacy: The PURPOSE trial</TI>
<SO>Journal of Vascular and Interventional Radiology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>8</NO>
<PG>1083-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schweizer-1996" MODIFIED="2013-12-11 11:18:00 +0000" MODIFIED_BY="Cathryn  A Broderick" NAME="Schweizer 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-12-11 11:18:00 +0000" MODIFIED_BY="Cathryn  A Broderick" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schweizer J, Altmann E, Stoblein F, Florek HJ, Kaulen R</AU>
<TI>Comparision of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions</TI>
<SO>European Journal of Radiology</SO>
<YR>1996</YR>
<VL>22</VL>
<PG>129-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-12-18 09:05:03 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Braithwaite-1997" MODIFIED="2009-11-29 06:50:13 +0000" MODIFIED_BY="[Empty name]" NAME="Braithwaite 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braithwaite BD, Buckenham TM, Galland RB, Heather BP, Earnshaw JJ</AU>
<TI>Prospective randomized trial of high-dose bolus versus low-dose tissue plasminogen activator infusion in the management of acute limb ischaemia</TI>
<SO>British Journal of Surgery</SO>
<YR>1997</YR>
<VL>84</VL>
<NO>5</NO>
<PG>646-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-29 06:50:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Braithwaite BD, Virgo H, Earnshaw JJ</AU>
<TI>The systematic effects of high dose bolus and low dose intra-arterial thrombolysis with tissue plasminogen activator (t-PA) for acute limb ischaemia</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1997</YR>
<VL>503 Abstract No PS-2058</VL>
<NO>Supplement June</NO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cina-1999" MODIFIED="2013-12-18 09:04:28 +0000" MODIFIED_BY="[Empty name]" NAME="Cina 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-12-18 09:04:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cina CS, Goh RH, Chan J, Kenny B, Evans G, Rawlinson J et al</AU>
<TI>Intraarterial catheter-directed thrombolysis: urokinase versus tissue plasminogen activator</TI>
<SO>Annals of Vascular Surgery</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>6</NO>
<PG>571-5</PG>
<IDENTIFIERS MODIFIED="2013-12-18 09:04:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dawson-1991" MODIFIED="2013-12-18 09:04:32 +0000" MODIFIED_BY="[Empty name]" NAME="Dawson 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-12-18 09:04:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dawson KJ, Reddy K, Platts AD, Hamilton G</AU>
<TI>Results of a recently instituted programme of thrombolytic therapy in acute lower limb ischaemia</TI>
<SO>British Journal of Surgery</SO>
<YR>1991</YR>
<VL>78</VL>
<NO>4</NO>
<PG>409-11</PG>
<IDENTIFIERS MODIFIED="2013-12-18 09:04:32 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dawson-1991a" MODIFIED="2013-12-18 09:04:37 +0000" MODIFIED_BY="[Empty name]" NAME="Dawson 1991a" YEAR="1991">
<REFERENCE MODIFIED="2013-12-18 09:04:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dawson KJ, Hehir D, Hamilton G</AU>
<TI>Low dose intra-arterial streptokinase compared with tissue plasminogen activator in acute lower limb ischaemia</TI>
<SO>Irish Journal of Medical Science</SO>
<YR>1991</YR>
<VL>160</VL>
<PG>216-7</PG>
<IDENTIFIERS MODIFIED="2013-12-18 09:04:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Didier-1995" MODIFIED="2013-12-18 09:04:44 +0000" MODIFIED_BY="[Empty name]" NAME="Didier 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-12-18 09:04:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Didier D, Meyerovitz MF, Vogel JJ, Soulier L, Bounameaux H</AU>
<TI>Thrombolysis versus mechanical recanalisation of chronic peripheral arterial occlusions. Randomized study</TI>
<SO>Schweizerische Medizinische Wochenschrift</SO>
<YR>1995</YR>
<VL>125</VL>
<PG>11</PG>
<IDENTIFIERS MODIFIED="2013-12-18 09:04:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dube-1996" MODIFIED="2009-11-29 06:43:05 +0000" MODIFIED_BY="[Empty name]" NAME="Dube 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-11-29 06:43:05 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded non randomized retrospective study&lt;/p&gt;" NOTES_MODIFIED="2009-11-29 06:43:05 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dube M, Soulez G, Therasse E, Cartier P, Blair JF, Roy P et al</AU>
<TI>Comparison of streptokinase and urokinase in local thrombolysis of peripheral arterial occlusions for lower limb salvage</TI>
<SO>Journal of Vascular and Interventional Radiology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>4</NO>
<PG>587-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duda-2001" MODIFIED="2013-12-11 11:19:18 +0000" MODIFIED_BY="[Empty name]" NAME="Duda 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-12-11 11:19:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duda S, Tepe G, Luz O, Ouriel K, Dietz K, Hahn U et al</AU>
<TI>Peripheral arterial occlusion: treatment with abxcimab plus urokinase versus urokinase alone - a randomised pilot trial (the PROMPT trial)</TI>
<SO>Radiology</SO>
<YR>2001</YR>
<VL>221</VL>
<PG>689-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gryglewski-1995" MODIFIED="2013-12-18 09:04:49 +0000" MODIFIED_BY="[Empty name]" NAME="Gryglewski 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-12-18 09:04:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gryglewski RJ, Szczeklik A, Korbut R, Swies J, Musial J, Krzanowski M et al</AU>
<TI>The mechanism of anti-thrombotic, thrombolytic and fibrinolytic actions of camonagrel--a new thromboxane synthase inhibitor</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>1995</YR>
<VL>107</VL>
<PG>283-9</PG>
<IDENTIFIERS MODIFIED="2013-12-18 09:04:49 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-2010" MODIFIED="2013-09-25 08:08:58 +0100" MODIFIED_BY="Karen Welch" NAME="Han 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-25 08:08:58 +0100" MODIFIED_BY="Karen Welch" NOTES="&lt;p&gt;20110153&lt;br&gt;Journal Article. Multicenter Study. Randomized Controlled Trial    STUDY 1 Partially double blinded  STUDY 2 double blinded&lt;/p&gt;" NOTES_MODIFIED="2013-09-25 08:08:58 +0100" NOTES_MODIFIED_BY="Karen Welch" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Han SM, Weaver FA, Comerota AJ, Perler BA, Joing M</AU>
<TI>Efficacy and safety of alfimeprase in patients with acute peripheral arterial occlusion (PAO)</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2010</YR>
<VL>51</VL>
<NO>3</NO>
<PG>600-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hess-1996" MODIFIED="2009-11-29 06:44:43 +0000" MODIFIED_BY="[Empty name]" NAME="Hess 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-11-29 06:44:43 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded open non-randomized&lt;/p&gt;" NOTES_MODIFIED="2009-11-29 06:44:43 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hess H, Mietaschk A, von Bilderling P, Neller P</AU>
<TI>Peripheral arterial occlusions: local low-dose thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA)</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>1996</YR>
<VL>12</VL>
<NO>1</NO>
<PG>97-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hiatt-2002" MODIFIED="2013-12-18 09:04:57 +0000" MODIFIED_BY="[Empty name]" NAME="Hiatt 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-12-18 09:04:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hiatt WR</AU>
<TI>Abciximab added to urokinase increased amputation-free survival in peripheral arterial occlusion of the legs</TI>
<SO>American College of Physicians Journal Club</SO>
<YR>2002</YR>
<VL>137</VL>
<NO>1</NO>
<PG>12</PG>
<IDENTIFIERS MODIFIED="2013-12-18 09:04:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reichle-1976" MODIFIED="2009-11-29 06:45:36 +0000" MODIFIED_BY="[Empty name]" NAME="Reichle 1976" YEAR="1976">
<REFERENCE MODIFIED="2009-11-29 06:45:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reichle FA, Rao NS, Chang KHY et al</AU>
<TI>Fibrinolytic treatment of acute or subacute arterial thrombosis</TI>
<SO>Surgical Forum</SO>
<YR>1976</YR>
<VL>27</VL>
<PG>219-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sarif-2005" MODIFIED="2009-11-29 06:48:58 +0000" MODIFIED_BY="[Empty name]" NAME="Sarif 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-29 06:48:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sarif J, Lindhoff-Last E, Bauersachs R</AU>
<TI>Rebound after discontinuation of long-term oral anticoagulation (OAC): Effects of a 4 week course of LMWH on VTE recurrences</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>1</NO>
<PG>Abstract no: P1024</PG>
<EN>1</EN>
<IDENTIFIERS MODIFIED="2009-04-07 16:24:27 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulman-1996" MODIFIED="2013-12-18 09:05:03 +0000" MODIFIED_BY="[Empty name]" NAME="Schulman 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-12-18 09:05:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulman S, Wiman B</AU>
<TI>The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1996</YR>
<VL>75</VL>
<PG>607-11</PG>
<IDENTIFIERS MODIFIED="2013-12-18 09:05:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-STILE-1994" MODIFIED="2013-12-18 09:03:19 +0000" MODIFIED_BY="[Empty name]" NAME="STILE 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-12-18 09:03:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The STILE investigators</AU>
<TI>Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischaemia of the lower extremity</TI>
<SO>Annals of Surgery</SO>
<YR>1994</YR>
<VL>220</VL>
<NO>3</NO>
<PG>251-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tepe-2006" MODIFIED="2009-11-29 06:47:12 +0000" MODIFIED_BY="[Empty name]" NAME="Tepe 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-11-29 06:47:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tepe G, Hopfenzitz C, Dietz K, Wiskirchen J, Heller S, Ouriel K et al</AU>
<TI>Peripheral Arteries: Treatment with antibodies of platelet receptors and reteplase for thrombolysis-APART trial</TI>
<SO>Radiology</SO>
<YR>2006</YR>
<VL>239</VL>
<NO>3</NO>
<PG>892-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanderschueren-1995" NAME="Vanderschueren 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vanderschueren S, Stockx L, Wilms G, Lacroix H, Verhaege R, Vermuylen J et al</AU>
<TI>Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase</TI>
<SO>Circulation</SO>
<YR>1995</YR>
<VL>92</VL>
<NO>8</NO>
<PG>2050-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wen-2005" MODIFIED="2009-11-29 06:47:52 +0000" MODIFIED_BY="[Empty name]" NAME="Wen 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-29 06:47:52 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Author citation changed from Cochrane library when paper was seen.&lt;/p&gt;" NOTES_MODIFIED="2009-11-29 06:47:52 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wen Y, Rong C, Yu W, Qian Z, Shu-rong L, Ning L et al</AU>
<TI>Effect of urokinase injected by volumetric infusion pump on rest pain, intermittent limp and walking distance in aged patients with arteriosclerosis obliterans of the lower limbs</TI>
<SO>Zhongguo Linchuang Kangfu</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>30</NO>
<PG>232-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2013-10-10 12:05:12 +0100" MODIFIED_BY="Heather Maxwell"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-12-18 09:10:50 +0000" MODIFIED_BY="Heather Maxwell">
<ADDITIONAL_REFERENCES MODIFIED="2013-12-18 09:10:50 +0000" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Anonymous-1986" MODIFIED="2009-11-29 06:53:18 +0000" MODIFIED_BY="[Empty name]" NAME="Anonymous 1986" TYPE="JOURNAL_ARTICLE">
<AU>Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery/North American Chapter International Society for Cardiovascular Surgery</AU>
<TI>Suggested standards for reports dealing with lower extremity ischaemia</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>1</NO>
<PG>80-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anonymous-1991" MODIFIED="2009-11-29 06:54:13 +0000" MODIFIED_BY="[Empty name]" NAME="Anonymous 1991" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Second European Consensus Document on chronic critical leg ischaemia</TI>
<SO>Circulation</SO>
<YR>1991</YR>
<VL>84 Suppl IV</VL>
<NO>4</NO>
<PG>1-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berridge-2013" MODIFIED="2013-12-18 09:10:50 +0000" MODIFIED_BY="[Empty name]" NAME="Berridge 2013" TYPE="COCHRANE_REVIEW">
<AU>Berridge DC, Kessel D, Robertson I</AU>
<TI>Surgery versus thrombolysis for initial management of acute limb ischaemia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2013-10-10 11:53:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-10 11:53:14 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002784.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fontaine-1954" NAME="Fontaine 1954" TYPE="JOURNAL_ARTICLE">
<AU>Fontaine VR, Kim M, Kieny R</AU>
<TI>Die chirurgische Behandlung der peripheren Durchblutungsstorungen</TI>
<TO>Die chirurgische Behandlung der peripheren Durchblutungsstorungen</TO>
<SO>Helvetica Chirurgica Acta</SO>
<YR>1954</YR>
<VL>5/6</VL>
<PG>499-533</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2010-02-17 11:10:34 +0000" MODIFIED_BY="Heather Maxwell" NAME="Higgins 2009" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kessel-2004" MODIFIED="2013-10-10 12:13:33 +0100" MODIFIED_BY="[Empty name]" NAME="Kessel 2004" TYPE="COCHRANE_REVIEW">
<AU>Kessel DO, Berridge DC, Robertson I</AU>
<TI>Infusion techniques for peripheral arterial thrombolysis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-08-11 10:53:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-11 10:53:53 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000985.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-10-10 11:44:37 +0100" MODIFIED_BY="Cathryn  A Broderick">
<REFERENCE ID="REF-Robertson-2010" MODIFIED="2013-10-10 11:44:37 +0100" MODIFIED_BY="Cathryn  A Broderick" NAME="Robertson 2010" TYPE="COCHRANE_REVIEW">
<AU>Robertson I, Kessel DO, Berridge DC</AU>
<TI>Fibrinolytic agents for peripheral arterial occlusion</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-10-10 11:44:37 +0100" MODIFIED_BY="Cathryn  A Broderick">
<IDENTIFIER MODIFIED="2013-10-10 11:44:37 +0100" MODIFIED_BY="Cathryn  A Broderick" TYPE="DOI" VALUE="10.1002/14651858.CD001099.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2010-02-10 11:07:33 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-12-11 11:23:13 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-12-11 10:59:03 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-12-21 09:59:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berridge-1991">
<CHAR_METHODS MODIFIED="2009-12-21 09:58:58 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT parallel group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-21 09:59:22 +0000" MODIFIED_BY="[Empty name]">
<P>Country: United Kingdom.</P>
<P>Setting: hospital.</P>
<P>No of patients: 60; 20 i.v. rt-PA, 20 i.a. SK, 20 i.a. rt-PA.</P>
<P>Mean age: 71 years.</P>
<P>Gender: 39 M; 21 F.</P>
<P>Inclusion criteria: peripheral lower limb ischaemia &lt;30 days duration.</P>
<P>Exclusion criteria: clinically apparent arterial emboli treated with surgical embolectomy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-21 09:59:35 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment: 3 infusion protocols.</P>
<P>(i) i.a. streptokinase infused at 5000 U/hr with 250 U/hr heparin (20pts);<BR/>(ii) i.a rt-PA 0.5 mg/hr with 250 U/hr heparin;<BR/>(iii) i.v. rt-PA max total dose 100 mg rt-PA at 4 rates of infusion 1, 2, 5 and 10 mg/hr.</P>
<P>Duration of treatment: complete lysis achieved or patient deterioration or lytic stagnation after a 12 hr period.</P>
<P>Follow up: 30 days and 3 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-29 06:23:29 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: limb salvage, amputation, death.</P>
<P>Secondary: death, major haemorrhage.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-10 12:17:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mahler-2001">
<CHAR_METHODS MODIFIED="2009-12-21 10:00:03 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: prospective RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-21 10:01:00 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Germany and Switzerland.</P>
<P>Setting: hospital.</P>
<P>No of patients: 234.</P>
<P>Mean age: 69.5 years rt-PA; 70.1 years UK.</P>
<P>Gender: M 81 (65%) rt-PA; M 64 (58%) UK.</P>
<P>Inclusion criteria: angiographically documented thrombotic or embolic occlusions five to 40 cm length.</P>
<P>Exclusion criteria: thrombi &gt; 6 months old or emboli &gt; 6 weeks. Standard exclusions for increased bleeding risk from thrombolysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-10 12:17:36 +0100" MODIFIED_BY="[Empty name]">
<P>(i) rt-PA;</P>
<P>(ii) UK;</P>
<P>Either end hole catheter or microporous balloon.</P>
<P>End hole catheter 2.5 mg/hr rt-PA or 100,000 IU/hr UK.</P>
<P>Microporous balloon 0.5 mg/cm thrombus length rt-PA or 20,000 IU/cm thrombus length.</P>
<P>Duration of treatment: end hole catheter serially advanced. Microporous balloon one hour if complete lysis not achieved then infusion lysis and secondary intervention.</P>
<P>Follow up: end of lysis and at six months; 81% reached six month follow up.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-29 06:25:55 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: vessel patency, time to lysis, amputation, death.</P>
<P>Secondary: complications including bleeding and cerebral haemorrhage.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-21 10:02:11 +0000" MODIFIED_BY="[Empty name]">
<P>Techniques not randomised - dependant on local practice - but use of rt-PA or UK was randomised. Complex trial as two infusion techniques used; the microporous balloon more rapid pharmacomechanical action but no difference in outcomes by technique or drug at follow up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-10 12:18:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meyerovitz-1990">
<CHAR_METHODS MODIFIED="2009-12-21 10:02:38 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-29 06:31:22 +0000" MODIFIED_BY="[Empty name]">
<P>Country: USA.</P>
<P>Setting: hospital.</P>
<P>No of patients: 32.</P>
<P>Mean age: 58 years.</P>
<P>Gender: 22 M and 10 F.</P>
<P>Inclusion criteria: native/bypass occlusion &lt; 90.</P>
<P>Exclusion criteria: standard exclusions for increased bleeding risk from thrombolysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-10 12:18:17 +0100" MODIFIED_BY="[Empty name]">
<P>(i) rt-PA 10 mg intrathrombic dose then 5 mg/hr up to 24 hours.</P>
<P>(ii) UK dose 60,000 IU intrathrombic bolus and 240,000 IU/h for two hrs, 120,000 IU/h for two hrs and 60,000 IU for up to 20 hours.</P>
<P>Duration of treatment: 24 hours.</P>
<P>Follow up: end of lysis for degree of lysis and surgery, angioplasty, death, limb loss within 30 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-29 06:28:51 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: 95% lysis and restoration of flow, time to lysis.</P>
<P>Secondary: surgery, angioplasty, death, limb loss within 30 days, blood transfusion (major haemorrhage) within 72 hours.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-21 10:11:27 +0000" MODIFIED_BY="[Empty name]">
<P>Lysis continued for 18 to 72 hours in 6 urokinase (4 successful).<BR/>Lysis continued for 2 pts with urokinase who received rt-PA unsuccessfully.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-21 10:08:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ouriel-1999">
<CHAR_METHODS MODIFIED="2009-12-21 10:07:20 +0000" MODIFIED_BY="[Empty name]">
<P>Phase II randomised, multicentre double blind study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-11-29 06:31:45 +0000" MODIFIED_BY="[Empty name]">
<P>Country: USA.</P>
<P>Setting: hospital.</P>
<P>No of patients: 241.</P>
<P>Mean age: 65.1 years.</P>
<P>Gender: M 143 (62.7%); F 85 (37.3%).</P>
<P>Inclusion criteria: patients with lower extremity native artery or graft occlusion of less than or equal to 14 days duration.</P>
<P>Exclusion criteria: standard exclusions for increased bleeding risk from thrombolysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-21 10:08:28 +0000" MODIFIED_BY="[Empty name]">
<P>(i) pro-urokinase 2 mg, 4 mg, 8 mg/hr for 8 hours followed by 0.5 mg/hr in each group. </P>
<P>(ii) urokinase group 4000 IU/min for 4 hours followed by 2000 IU/min. Thrombus lacing dose based on length of occlusion.</P>
<P>Duration of treatment: &gt; 95% clot lysis or 24 hours.</P>
<P>Follow up: 30 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-29 06:32:17 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: vessel patency, time to lysis, dose of study drug, amputation, death.</P>
<P>Secondary: complications including bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-29 06:32:22 +0000" MODIFIED_BY="[Empty name]">
<P>Dose response curve for pro-urokinase derived. Fibrin specificity of prourokinase lost at equipotent doses with urokinase.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-21 10:11:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schweizer-1996">
<CHAR_METHODS MODIFIED="2009-12-21 10:09:31 +0000" MODIFIED_BY="[Empty name]">
<P>Study design: RCT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-21 10:11:53 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Germany.</P>
<P>Setting: hospital.</P>
<P>No of patients: 120; 60 rt-PA, 60 UK.</P>
<P>Mean age: 65 years.</P>
<P>Gender: M 60%, F 40% UK; M 57%, F 43% rt-PA.</P>
<P>Inclusion criteria: &lt; 3 months occlusion of femoropopliteal segment.</P>
<P>Exclusion criteria: not recorded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-21 10:10:35 +0000" MODIFIED_BY="[Empty name]">
<P>(i) rt-PA 5 mg intrathrombic bolus followed by infusion at 5 mg/hr plus heparin 750 IU/hr.<BR/>(ii) urokinase 60,000 IU/hr plus heparin 700 IU/hr.</P>
<P>Treatment duration: rt-PA 1 to 4 hrs (mean 2 hrs); UK 6 to 72 hrs (mean 24 hours).</P>
<P>Follow up: 6 months follow up.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-29 06:33:55 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: amputation, Fontaine, ABPI, vessel patency.</P>
<P>Secondary: death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Fontaine IIb claudication 49% of study population. Short occlusion lengths 6 cm.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>i.a. intra-arterial<BR/>IU international units<BR/>i.v. intravenous<BR/>RCT randomised controlled trial<BR/>rt-PA recombinant tissue plasminogen activator<BR/>SK streptokinase<BR/>UK urokinase</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-12-11 11:23:13 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-11-29 06:34:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Braithwaite-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-29 06:34:24 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of dose regimes for high and low dose rt-PA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-29 06:34:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cina-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-29 06:34:29 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of rt-Pa versus urokinase but non-randomised selection by surgeons preference</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-29 06:34:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dawson-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-29 06:34:36 +0000" MODIFIED_BY="[Empty name]">
<P>Non-randomised streptokinase vs rt-PA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-29 06:34:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dawson-1991a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-29 06:34:44 +0000" MODIFIED_BY="[Empty name]">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-29 06:34:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Didier-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-29 06:34:48 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of angioplasty versus rt-PA and angioplasty</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-11 11:16:13 +0000" MODIFIED_BY="Cathryn  A Broderick" STUDY_ID="STD-Dube-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-11 11:16:13 +0000" MODIFIED_BY="Cathryn  A Broderick">
<P>Only partially randomised 10 of 40 patients; insufficient for analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-29 13:16:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Duda-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-29 13:16:52 +0000" MODIFIED_BY="[Empty name]">
<P>Not a true comparison of agents; use of abxicimab as an adjunctive agent studied. Complex randomisation 5:2 to support complication rate as major finding may have impact on study findings</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-31 15:15:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gryglewski-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-31 15:15:47 +0000" MODIFIED_BY="[Empty name]">
<P>Not a comparison of thrombolytic agents</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-11 11:16:07 +0000" MODIFIED_BY="Cathryn  A Broderick" STUDY_ID="STD-Han-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-11 11:16:07 +0000" MODIFIED_BY="Cathryn  A Broderick">
<P>Paper reports NAPA II/III trials. Not a comparison of thrombolytic agents - comparison with placebo. Safety and efficacy trial with primary end point of avoidance of open vascular surgery within 30 days of treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-29 06:35:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hess-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-29 06:35:15 +0000" MODIFIED_BY="[Empty name]">
<P>Non-comparative and non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-31 15:25:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hiatt-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-31 15:25:31 +0000" MODIFIED_BY="[Empty name]">
<P>Not a comparison of agents </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-29 13:17:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reichle-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-29 13:17:01 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised but 11 patients in one group and 6 in the other group - method of randomisation not stated, clinical enrolment criteria not accurately described</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-31 15:25:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sarif-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-31 15:25:51 +0000" MODIFIED_BY="[Empty name]">
<P>Not arterial thrombolysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-31 15:27:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schulman-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-31 15:27:02 +0000" MODIFIED_BY="[Empty name]">
<P>Venous thromboembolism</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-29 06:35:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-STILE-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-29 06:35:50 +0000" MODIFIED_BY="[Empty name]">
<P>Subset of patients comparing urokinase and rt-PA but insufficient detail reported to permit analysis. Authors report no difference between rt-PA and urokinase<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-11 11:23:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tepe-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-11 11:23:13 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison is of the effect of the addition of abxicimab to thrombolytic agents and not a true comparison of agents. More appropriately considered under infusion techniques</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-29 06:36:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vanderschueren-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-29 06:36:13 +0000" MODIFIED_BY="[Empty name]">
<P>Staphylokinase. Pilot study. No apparent randomisation. Not blinded. No control group - study compared two different infusion protocols</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-29 06:36:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-29 06:36:23 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of urokinase and danshen root</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>rt-PA recombinant tissue plasminogen activator</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-10-10 12:05:12 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-12-11 10:59:03 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-08-19 16:29:16 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 12:46:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berridge-1991">
<DESCRIPTION>
<P>Random number generator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 16:29:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mahler-2001">
<DESCRIPTION>
<P>Randomised in blocks of 10.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 14:04:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meyerovitz-1990">
<DESCRIPTION>
<P>Randomised by means of consecutive numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 14:16:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ouriel-1999">
<DESCRIPTION>
<P>Randomisation was stratified by type of occlusion; native artery or bypass graft.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 14:22:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schweizer-1996">
<DESCRIPTION>
<P>States randomised but method not given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-08-19 14:23:04 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 12:47:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berridge-1991">
<DESCRIPTION>
<P>Information on allocation concealment not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 12:53:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mahler-2001">
<DESCRIPTION>
<P>Method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 14:05:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meyerovitz-1990">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 14:17:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ouriel-1999">
<DESCRIPTION>
<P>Method not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 14:23:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schweizer-1996">
<DESCRIPTION>
<P>Not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-08-19 14:33:40 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-19 12:48:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Berridge-1991">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-19 12:54:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mahler-2001">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-19 14:06:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Meyerovitz-1990">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-19 14:18:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ouriel-1999">
<DESCRIPTION>
<P>Double blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-19 14:33:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schweizer-1996">
<DESCRIPTION>
<P>Not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-12-21 10:09:55 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-21 09:59:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berridge-1991">
<DESCRIPTION>
<P>Exclusions post-randomisation: 6 not included in the analysis.</P>
<P>Lost to follow up: none.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-21 10:00:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mahler-2001">
<DESCRIPTION>
<P>55 patients lost to follow up but no information on statistical handling of missing data.</P>
<P>Exclusion post-randomisation: none recorded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-21 10:03:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meyerovitz-1990">
<DESCRIPTION>
<P>Exclusions post-randomisation: none recorded.</P>
<P>No losses to follow up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-21 10:07:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ouriel-1999">
<DESCRIPTION>
<P>All analyses based on participants who received their randomised treatment. Of 241 patients randomised 13 patients were entered into the trial but never received the specified therapy (reasons given). No losses to follow up recorded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-21 10:09:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schweizer-1996">
<DESCRIPTION>
<P>Exclusions post-randomisation: none recorded.</P>
<P>Two patients lost to follow-up but no information on statistical handling of missing data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-08-19 14:27:45 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 12:50:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Berridge-1991">
<DESCRIPTION>
<P>All outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 12:57:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mahler-2001">
<DESCRIPTION>
<P>All primary and secondary outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 14:08:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meyerovitz-1990">
<DESCRIPTION>
<P>All outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 14:21:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ouriel-1999">
<DESCRIPTION>
<P>All outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 14:27:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schweizer-1996">
<DESCRIPTION>
<P>All outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-12-11 10:59:03 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 12:51:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Berridge-1991">
<DESCRIPTION>
<P>Study financially supported by Boehringer Ingelheim who supplied recombinant tissue plasminogen activator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-29 06:26:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mahler-2001">
<DESCRIPTION>
<P>Supported by a grant from Boehringer Ingelheim who manufactured the Alteplase.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-29 06:29:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meyerovitz-1990">
<DESCRIPTION>
<P>Supported in part by Genentech Inc (Activase manufacturer) and Abbott Laboratories (Abbokinase manufacturer).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-19 14:21:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ouriel-1999">
<DESCRIPTION>
<P>Some authors were affiliated to Abbott Laboratories manufacturers of Abbokinase.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-11 10:59:03 +0000" MODIFIED_BY="Cathryn  A Broderick" RESULT="UNKNOWN" STUDY_ID="STD-Schweizer-1996">
<DESCRIPTION>
<P>No declarations of interest stated, no information given regarding sponsorship.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-02-03 15:37:42 +0000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-12-18 09:08:36 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-12-18 14:37:26 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Intra-arterial streptokinase versus intravenous rt-PA</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-12-18 14:35:40 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Vessel Patency immediately post lysis</NAME>
<GROUP_LABEL_1>i.a streptokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.v. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rt-PA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.a. strept.</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.94240698639235" CI_START="1.198513027249428" EFFECT_SIZE="4.888888888888889" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="1.2997775751301495" LOG_CI_START="0.07864275896357571" LOG_EFFECT_SIZE="0.6892101670468626" MODIFIED="2009-07-15 21:12:09 +0100" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.7173006357310734" STUDY_ID="STD-Berridge-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.514520202020202" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-09-02 14:55:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Asymptomatic Limb salvage at 30 days</NAME>
<GROUP_LABEL_1>i.a. streptokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.v. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours i.v. rt-PA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.a. strept.</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.4344479795211456" CI_START="0.5223619993212295" EFFECT_SIZE="1.8333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.8085112940948943" LOG_CI_START="-0.2820284245457314" LOG_EFFECT_SIZE="0.2632414347745814" MODIFIED="2009-07-15 21:30:16 +0100" MODIFIED_BY="[Empty name]" ORDER="30671" O_E="0.0" SE="0.6405884289881728" STUDY_ID="STD-Berridge-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.41035353535353536" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-15 21:33:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Amputation at 30 days</NAME>
<GROUP_LABEL_1>i.a. streptokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.v. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours i.a. strept.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.v. rt-PA</GRAPH_LABEL_2>
<DICH_DATA CI_END="432.58173311735743" CI_START="1.1993737154709485" EFFECT_SIZE="22.77777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.6360681762823814" LOG_CI_START="0.07895452695047733" LOG_EFFECT_SIZE="1.3575113516164294" MODIFIED="2009-07-15 21:15:49 +0100" MODIFIED_BY="[Empty name]" ORDER="30672" O_E="0.0" SE="1.502061215534269" STUDY_ID="STD-Berridge-1991" TOTAL_1="20" TOTAL_2="20" VAR="2.2561878952122854" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-15 21:24:09 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>i.a. streptokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.v. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours i.a. strept.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.v. rt-PA</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1456674740237" CI_START="0.028277129425058976" EFFECT_SIZE="0.2982456140350877" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4977128117935357" LOG_CI_START="-1.5485646803819706" LOG_EFFECT_SIZE="-0.5254259342942175" MODIFIED="2009-07-15 21:17:07 +0100" MODIFIED_BY="[Empty name]" ORDER="30673" O_E="0.0" SE="1.201993528140841" STUDY_ID="STD-Berridge-1991" TOTAL_1="20" TOTAL_2="20" VAR="1.4447884416924663" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-12-18 14:37:10 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="96.01" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Complications- major haemorrhage</NAME>
<GROUP_LABEL_1>i.a. streptokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.v. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours i.a. strept.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.v. rt-PA</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.67331316667771" CI_START="0.17626384629593778" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.753836757265777" LOG_CI_START="-0.753836757265777" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-15 21:40:43 +0100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.8856148855400953" STUDY_ID="STD-Berridge-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.7843137254901961" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-12-18 14:37:26 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Complications- minor haemorrhage</NAME>
<GROUP_LABEL_1>i.a. streptokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.v. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours i.a. strept.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.v. rt-PA</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9771318903515679" CI_START="0.04760930379130353" EFFECT_SIZE="0.21568627450980393" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="-0.010046812549357036" LOG_CI_START="-1.3223081693300658" LOG_EFFECT_SIZE="-0.6661774909397113" MODIFIED="2009-07-15 21:40:02 +0100" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.7708288167714672" STUDY_ID="STD-Berridge-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.5941770647653001" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-12-18 14:42:01 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Intra-arterial streptokinase versus intra-arterial rt-PA</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-12-18 14:40:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Vessel patency immediately post lysis</NAME>
<GROUP_LABEL_1>i.a. streptokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.a. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours i.a. rt-PA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.a.strept</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7833591723195934" CI_START="0.004484730266923516" EFFECT_SIZE="0.08943089430894309" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.2512388198143818" LOG_CI_START="-2.3482636723767274" LOG_EFFECT_SIZE="-1.048512426281173" MODIFIED="2009-07-15 21:27:16 +0100" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="1.5269606316579223" STUDY_ID="STD-Berridge-1991" TOTAL_1="20" TOTAL_2="20" VAR="2.331608770633161" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-09-02 14:58:08 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Asymptomatic Limb salvage at 30 days</NAME>
<GROUP_LABEL_1>i.a. streptokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.a. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours i.a. rt-PA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.a. strept.</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5428832628915532" CI_START="0.09114429029222304" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="16" LOG_CI_END="0.18833306786487122" LOG_CI_START="-1.0402705324094335" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="30674" O_E="0.0" SE="0.7216878364870322" STUDY_ID="STD-Berridge-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.5208333333333333" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-15 21:33:46 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Amputation at 30 days</NAME>
<GROUP_LABEL_1>i.a. streptokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.a. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours i.a. strept.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.a. rt-PA</GRAPH_LABEL_2>
<DICH_DATA CI_END="93.34135862966997" CI_START="1.121353284223398" EFFECT_SIZE="10.23076923076923" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.9700741179662615" LOG_CI_START="0.049742459354236455" LOG_EFFECT_SIZE="1.009908288660249" ORDER="30675" O_E="0.0" SE="1.1280123220637213" STUDY_ID="STD-Berridge-1991" TOTAL_1="20" TOTAL_2="20" VAR="1.2724117987275883" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-07-15 21:24:27 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>i.a. streptokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.a. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours i.a. strept.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.a. rt-PA</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7598005427135255" CI_START="0.07157432616609029" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.44087769571411367" LOG_CI_START="-1.1452427319368386" LOG_EFFECT_SIZE="-0.35218251811136253" ORDER="30676" O_E="0.0" SE="0.9316949906249123" STUDY_ID="STD-Berridge-1991" TOTAL_1="20" TOTAL_2="20" VAR="0.8680555555555556" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-12-18 14:41:36 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="210.89" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Complications- major haemorrhage</NAME>
<GROUP_LABEL_1>i.a. streptokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.a. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours i.a. strept</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.a. rt-PA.</GRAPH_LABEL_2>
<DICH_DATA CI_END="169.89878129926606" CI_START="0.3957650519079413" EFFECT_SIZE="8.2" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.230190263643018" LOG_CI_START="-0.4025625588755845" LOG_EFFECT_SIZE="0.9138138523837167" MODIFIED="2009-07-15 21:42:07 +0100" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="1.5464920402840814" STUDY_ID="STD-Berridge-1991" TOTAL_1="20" TOTAL_2="20" VAR="2.391637630662021" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-12-18 14:42:01 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Complications- minor haemorrhage</NAME>
<GROUP_LABEL_1>i.a. streptokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.a. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours i.a.strept.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.a.rt-PA</GRAPH_LABEL_2>
<DICH_DATA CI_END="169.89878129926606" CI_START="0.3957650519079413" EFFECT_SIZE="8.2" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.230190263643018" LOG_CI_START="-0.4025625588755845" LOG_EFFECT_SIZE="0.9138138523837167" MODIFIED="2009-07-15 21:43:17 +0100" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="1.5464920402840814" STUDY_ID="STD-Berridge-1991" TOTAL_1="20" TOTAL_2="20" VAR="2.391637630662021" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-12-18 09:08:36 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Intra-arterial urokinase versus intra-arterial rt-PA</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="105" EVENTS_2="136" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-12-18 15:02:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="186" TOTAL_2="200" WEIGHT="0.0" Z="0.0">
<NAME>Vessel patency immediately post lysis</NAME>
<GROUP_LABEL_1>i.a. urokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.a. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours i.a. rt-PA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.a. urokinase</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0275918265437867" CI_START="0.3625714674324577" EFFECT_SIZE="0.6103896103896104" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="77" LOG_CI_END="0.011820641233615118" LOG_CI_START="-0.440606375707144" LOG_EFFECT_SIZE="-0.21439286723676443" MODIFIED="2009-09-02 15:03:14 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.26575786930085477" STUDY_ID="STD-Mahler-2001" TOTAL_1="110" TOTAL_2="124" VAR="0.07062724509533021" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.4546575331335054" CI_START="0.14665996993089303" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.38999090914934675" LOG_CI_START="-0.8336884083820595" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2009-08-02 19:29:32 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.7187952884282608" STUDY_ID="STD-Meyerovitz-1990" TOTAL_1="16" TOTAL_2="16" VAR="0.5166666666666666" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2065866330484993" CI_START="0.1951872946145682" EFFECT_SIZE="0.4852941176470588" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="51" LOG_CI_END="0.0815585097542689" LOG_CI_START="-0.7095484554109667" LOG_EFFECT_SIZE="-0.3139949728283488" MODIFIED="2009-08-02 19:26:28 +0100" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.46470014738069404" STUDY_ID="STD-Schweizer-1996" TOTAL_1="60" TOTAL_2="60" VAR="0.21594622697563876" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2573042104619905" CI_END="4.1474188554522735" CI_START="0.6792615964706827" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.678446410519896" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="178" I2="38.59953290281304" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.617777897776795" LOG_CI_START="-0.16796293849676772" LOG_EFFECT_SIZE="0.22490747964001365" METHOD="MH" MODIFIED="2009-10-28 12:44:46 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.19619400749704552" P_Q="1.0" P_Z="0.26185168908070167" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="176" TOTAL_2="192" WEIGHT="100.0" Z="1.1220253284497232">
<NAME>Limb salvage</NAME>
<GROUP_LABEL_1>i.a. urokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.a. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours i.a. urokin.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.a. rt-PA</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.786802329379906" CI_START="0.9427392259480564" EFFECT_SIZE="3.471976401179941" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="113" LOG_CI_END="1.1067619514892253" LOG_CI_START="-0.025608422208520155" LOG_EFFECT_SIZE="0.5405767646403525" MODIFIED="2009-10-28 12:44:46 +0000" MODIFIED_BY="[Empty name]" ORDER="30677" O_E="0.0" SE="0.665159962833807" STUDY_ID="STD-Mahler-2001" TOTAL_1="110" TOTAL_2="124" VAR="0.44243777615707147" WEIGHT="38.51725607158074"/>
<DICH_DATA CI_END="4.316131752998608" CI_START="0.08878782590042258" EFFECT_SIZE="0.6190476190476191" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.6350946933618754" LOG_CI_START="-1.0516465782160405" LOG_EFFECT_SIZE="-0.20827594242708247" ORDER="30678" O_E="0.0" SE="0.9908001724288211" STUDY_ID="STD-Meyerovitz-1990" TOTAL_1="16" TOTAL_2="16" VAR="0.9816849816849816" WEIGHT="34.89561141883255"/>
<DICH_DATA CI_END="5.359270723652739" CI_START="0.041321533957944016" EFFECT_SIZE="0.47058823529411764" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="51" LOG_CI_END="0.7291056959909592" LOG_CI_START="-1.38382356476362" LOG_EFFECT_SIZE="-0.32735893438633035" ORDER="30679" O_E="0.0" SE="1.2411451069357637" STUDY_ID="STD-Schweizer-1996" TOTAL_1="50" TOTAL_2="52" VAR="1.5404411764705883" WEIGHT="26.587132509586706"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4721868646716003" CI_START="0.24111381918548724" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5957890545282597" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.1679629384967678" LOG_CI_START="-0.617777897776795" LOG_EFFECT_SIZE="-0.22490747964001362" METHOD="MH" MODIFIED="2013-12-18 09:08:36 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.19619400749704552" P_Q="1.0" P_Z="0.26185168908070167" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="176" TOTAL_2="192" WEIGHT="0.0" Z="1.1220253284497232">
<NAME>Major amputation at 30 days-6 months</NAME>
<GROUP_LABEL_1>i.a. urokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.a. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours i.a. urokin.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.a. rt-PA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0607387201846408" CI_START="0.0782056353293525" EFFECT_SIZE="0.28802039082412917" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.025608422208520238" LOG_CI_START="-1.1067619514892253" LOG_EFFECT_SIZE="-0.5405767646403525" MODIFIED="2009-10-28 12:46:44 +0000" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.665159962833807" STUDY_ID="STD-Mahler-2001" TOTAL_1="110" TOTAL_2="124" VAR="0.44243777615707147" WEIGHT="0.0"/>
<DICH_DATA CI_END="11.262805343623583" CI_START="0.2316889421425228" EFFECT_SIZE="1.6153846153846154" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0516465782160402" LOG_CI_START="-0.6350946933618754" LOG_EFFECT_SIZE="0.2082759424270825" MODIFIED="2009-07-15 22:00:04 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.9908001724288211" STUDY_ID="STD-Meyerovitz-1990" TOTAL_1="16" TOTAL_2="16" VAR="0.9816849816849816" WEIGHT="0.0"/>
<DICH_DATA CI_END="24.2004568614944" CI_START="0.18659255177884093" EFFECT_SIZE="2.125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.38382356476362" LOG_CI_START="-0.7291056959909592" LOG_EFFECT_SIZE="0.32735893438633035" MODIFIED="2009-08-02 19:41:58 +0100" MODIFIED_BY="[Empty name]" ORDER="30680" O_E="0.0" SE="1.2411451069357637" STUDY_ID="STD-Schweizer-1996" TOTAL_1="50" TOTAL_2="52" VAR="1.5404411764705883" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.04622966531416141" CI_END="2.53679569610771" CI_START="0.24415402361229313" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.786999921402185" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" I2_Q="100.00000000000001" ID="CMP-003.04" LOG_CI_END="0.40428549220168053" LOG_CI_START="-0.6123361142296735" LOG_EFFECT_SIZE="-0.1040253110139965" METHOD="MH" MODIFIED="2009-08-02 19:44:35 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.82975901841492" P_Q="0.0" P_Z="0.6883430259218831" Q="2.1602628727950547E-33" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="176" TOTAL_2="192" WEIGHT="100.0" Z="0.4011047213204751">
<NAME>Death</NAME>
<GROUP_LABEL_1>i.a. urokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.a. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours i.a. urokin.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.a. rt-PA</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7015727920625623" CI_START="0.20386989167804404" EFFECT_SIZE="0.7421383647798742" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.43161667380569585" LOG_CI_START="-0.6906469078343481" LOG_EFFECT_SIZE="-0.12951511701432614" MODIFIED="2009-08-02 18:29:29 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.6592231831496856" STUDY_ID="STD-Mahler-2001" TOTAL_1="110" TOTAL_2="124" VAR="0.434575205202004" WEIGHT="84.97995755717992"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-15 22:41:54 +0100" MODIFIED_BY="[Empty name]" ORDER="30681" O_E="0.0" SE="0.0" STUDY_ID="STD-Meyerovitz-1990" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="17.105581617049836" CI_START="0.06333012520854071" EFFECT_SIZE="1.0408163265306123" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2331378454770001" LOG_CI_START="-1.1983896533381546" LOG_EFFECT_SIZE="0.017374096069422723" ORDER="30682" O_E="0.0" SE="1.4282912890592594" STUDY_ID="STD-Schweizer-1996" TOTAL_1="50" TOTAL_2="52" VAR="2.0400160064025608" WEIGHT="15.02004244282009"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1143280602970393" CI_END="2.4013794106169812" CI_START="0.1938986748311704" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6823666796418841" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.3804607826807663" LOG_CI_START="-0.7124251590258687" LOG_EFFECT_SIZE="-0.16598218817255114" METHOD="MH" MODIFIED="2009-08-02 19:44:38 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5728314353299178" P_Q="1.0" P_Z="0.5516165289241458" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="142" TOTAL_2="156" WEIGHT="99.99999999999999" Z="0.595339547300493">
<NAME>Complications - major haemorrhage</NAME>
<GROUP_LABEL_1>i.a. urokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.a. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours i.a. urokin.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.a. rt-PA</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.239564568540828" CI_START="0.01502157065748869" EFFECT_SIZE="0.37254901960784315" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.965651504776831" LOG_CI_START="-1.823284655067046" LOG_EFFECT_SIZE="-0.4288165751451074" MODIFIED="2009-08-02 18:37:59 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="1.638234905748936" STUDY_ID="STD-Mahler-2001" TOTAL_1="110" TOTAL_2="124" VAR="2.6838136064142253" WEIGHT="23.71519047268366"/>
<DICH_DATA CI_END="2.620351312576079" CI_START="0.09836523753623866" EFFECT_SIZE="0.5076923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.41835952142850813" LOG_CI_START="-1.0071583549584444" LOG_EFFECT_SIZE="-0.2943994167649681" MODIFIED="2009-07-15 22:42:43 +0100" MODIFIED_BY="[Empty name]" ORDER="30683" O_E="0.0" SE="0.8373562570169887" STUDY_ID="STD-Meyerovitz-1990" TOTAL_1="16" TOTAL_2="16" VAR="0.7011655011655012" WEIGHT="68.58805087687921"/>
<DICH_DATA CI_END="84.43375706862079" CI_START="0.1207899737594254" EFFECT_SIZE="3.193548387096774" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.926516114606243" LOG_CI_START="-0.9179691130796888" LOG_EFFECT_SIZE="0.5042735007632773" MODIFIED="2009-07-15 22:42:55 +0100" MODIFIED_BY="[Empty name]" ORDER="30684" O_E="0.0" SE="1.6708647031716797" STUDY_ID="STD-Schweizer-1996" TOTAL_1="16" TOTAL_2="16" VAR="2.7917888563049855" WEIGHT="7.696758650437124"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6230890835714943" CI_END="1.2565174637470444" CI_START="0.2002666854991652" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5016359115299044" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.09916852902590352" LOG_CI_START="-0.6983912898837544" LOG_EFFECT_SIZE="-0.2996113804289255" METHOD="MH" MODIFIED="2009-08-02 19:44:38 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.7323150342222035" P_Q="1.0" P_Z="0.14086960115525088" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="186" TOTAL_2="200" WEIGHT="100.0" Z="1.4725604301425816">
<NAME>Complications - minor haemorrhage</NAME>
<GROUP_LABEL_1>i.a. urokinase</GROUP_LABEL_1>
<GROUP_LABEL_2>i.a. rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours i.a. urokin.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours i.a. rt-PA</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.554439575281628" CI_START="0.12249144755044107" EFFECT_SIZE="0.7469135802469136" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.658434944572101" LOG_CI_START="-0.9118942330244628" LOG_EFFECT_SIZE="-0.12672964422618088" MODIFIED="2009-08-02 18:39:56 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.9224191321750161" STUDY_ID="STD-Mahler-2001" TOTAL_1="110" TOTAL_2="124" VAR="0.8508570554025099" WEIGHT="20.595658758202926"/>
<DICH_DATA CI_END="3.969340472777186" CI_START="0.007782332014105859" EFFECT_SIZE="0.17575757575757575" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5987183523983605" LOG_CI_START="-2.108890245028261" LOG_EFFECT_SIZE="-0.7550859463149502" ORDER="30685" O_E="0.0" SE="1.5904626930071135" STUDY_ID="STD-Meyerovitz-1990" TOTAL_1="16" TOTAL_2="16" VAR="2.52957157784744" WEIGHT="18.046441191317516"/>
<DICH_DATA CI_END="1.6395369289318733" CI_START="0.16186343770603107" EFFECT_SIZE="0.5151515151515151" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.21472120316501409" LOG_CI_START="-0.7908512401642411" LOG_EFFECT_SIZE="-0.2880650184996136" MODIFIED="2009-07-15 22:44:32 +0100" MODIFIED_BY="[Empty name]" ORDER="30686" O_E="0.0" SE="0.5906782308754778" STUDY_ID="STD-Schweizer-1996" TOTAL_1="60" TOTAL_2="60" VAR="0.3489007724301842" WEIGHT="61.35790005047956"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-12-11 10:59:04 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-09-25 08:04:34 +0100" MODIFIED_BY="Karen Welch" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoIAAAMoCAYAAABbAIEpAABnb0lEQVR42uzdD4RW6f8//g9ZyVor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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-12-11 10:59:04 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASQAAAGwCAIAAACPbI/uAAAUNElEQVR42u3dsY4cxxWF4QEMGA42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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-12-11 10:59:04 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-09-25 07:51:50 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-09-25 07:51:50 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-09-25 07:48:43 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-09-25 07:51:50 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="45">
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>MeSH descriptor: [Thrombolytic Therapy] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>1556</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>MeSH descriptor: [Fibrinolytic Agents] this term only and with qualifiers: [Administration &amp; dosage - AD]</P>
</TD>
<TD ALIGN="RIGHT">
<P>596</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>MeSH descriptor: [Plasminogen Activators] explode all trees and with qualifiers: [Administration &amp; dosage - AD]</P>
</TD>
<TD ALIGN="RIGHT">
<P>662</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>urokinase or streptokinase or streptase or tenecteplase:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>1885</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>reteplase or alteplase:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>413</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>anistreplase or prourokinase or retavase or rapilysin:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>206</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>t-PA or tPA:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>954</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>r-PA or rPA:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>53</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>lysis:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>691</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>plasminogen near/2 activator</P>
</TD>
<TD ALIGN="RIGHT">
<P>3004</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>clot near/3 (bust* or break* or remov*):ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>54</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>thrombolysis</P>
</TD>
<TD ALIGN="RIGHT">
<P>2457</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12</P>
</TD>
<TD ALIGN="RIGHT">
<P>6691</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>893</P>
</TD>
</TR>
<TR>
<TD>
<P>#15</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriolosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>#16</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriosclerosis Obliterans] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>71</P>
</TD>
</TR>
<TR>
<TD>
<P>#17</P>
</TD>
<TD>
<P>MeSH descriptor: [Atherosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>382</P>
</TD>
</TR>
<TR>
<TD>
<P>#18</P>
</TD>
<TD>
<P>MeSH descriptor: [Arterial Occlusive Diseases] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>755</P>
</TD>
</TR>
<TR>
<TD>
<P>#19</P>
</TD>
<TD>
<P>MeSH descriptor: [Intermittent Claudication] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>711</P>
</TD>
</TR>
<TR>
<TD>
<P>#20</P>
</TD>
<TD>
<P>MeSH descriptor: [Ischemia] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>753</P>
</TD>
</TR>
<TR>
<TD>
<P>#21</P>
</TD>
<TD>
<P>MeSH descriptor: [Peripheral Vascular Diseases] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>2150</P>
</TD>
</TR>
<TR>
<TD>
<P>#22</P>
</TD>
<TD>
<P>MeSH descriptor: [Vascular Diseases] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>381</P>
</TD>
</TR>
<TR>
<TD>
<P>#23</P>
</TD>
<TD>
<P>MeSH descriptor: [Leg] explode all trees and with qualifiers: [Blood supply - BS]</P>
</TD>
<TD ALIGN="RIGHT">
<P>1075</P>
</TD>
</TR>
<TR>
<TD>
<P>#24</P>
</TD>
<TD>
<P>MeSH descriptor: [Femoral Artery] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>720</P>
</TD>
</TR>
<TR>
<TD>
<P>#25</P>
</TD>
<TD>
<P>MeSH descriptor: [Popliteal Artery] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>250</P>
</TD>
</TR>
<TR>
<TD>
<P>#26</P>
</TD>
<TD>
<P>MeSH descriptor: [Iliac Artery] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>151</P>
</TD>
</TR>
<TR>
<TD>
<P>#27</P>
</TD>
<TD>
<P>MeSH descriptor: [Tibial Arteries] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>29</P>
</TD>
</TR>
<TR>
<TD>
<P>#28</P>
</TD>
<TD>
<P>(atherosclero* or arteriosclero* or PVD or PAOD or PAD)</P>
</TD>
<TD ALIGN="RIGHT">
<P>17195</P>
</TD>
</TR>
<TR>
<TD>
<P>#29</P>
</TD>
<TD>
<P>(arter*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>4872</P>
</TD>
</TR>
<TR>
<TD>
<P>#30</P>
</TD>
<TD>
<P>(vascular) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>1378</P>
</TD>
</TR>
<TR>
<TD>
<P>#31</P>
</TD>
<TD>
<P>(vein*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>713</P>
</TD>
</TR>
<TR>
<TD>
<P>#32</P>
</TD>
<TD>
<P>(veno*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>976</P>
</TD>
</TR>
<TR>
<TD>
<P>#33</P>
</TD>
<TD>
<P>(peripher*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>1358</P>
</TD>
</TR>
<TR>
<TD>
<P>#34</P>
</TD>
<TD>
<P>(peripheral near/3 (dis* or thrombo*))</P>
</TD>
<TD ALIGN="RIGHT">
<P>3349</P>
</TD>
</TR>
<TR>
<TD>
<P>#35</P>
</TD>
<TD>
<P>arteriopathic</P>
</TD>
<TD ALIGN="RIGHT">
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>#36</P>
</TD>
<TD>
<P>(claudic* or hinken*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>1436</P>
</TD>
</TR>
<TR>
<TD>
<P>#37</P>
</TD>
<TD>
<P>(isch* or CLI)</P>
</TD>
<TD ALIGN="RIGHT">
<P>16827</P>
</TD>
</TR>
<TR>
<TD>
<P>#38</P>
</TD>
<TD>
<P>dysvascular*</P>
</TD>
<TD ALIGN="RIGHT">
<P>14</P>
</TD>
</TR>
<TR>
<TD>
<P>#39</P>
</TD>
<TD>
<P>leg near/4 (obstruct* or occlus* or steno* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>176</P>
</TD>
</TR>
<TR>
<TD>
<P>#40</P>
</TD>
<TD>
<P>limb near/4 (obstruct* or occlus* or steno* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>228</P>
</TD>
</TR>
<TR>
<TD>
<P>#41</P>
</TD>
<TD>
<P>(lower near/3 extrem*) near/4 (obstruct* or occlus* or steno* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>137</P>
</TD>
</TR>
<TR>
<TD>
<P>#42</P>
</TD>
<TD>
<P>(aort* or iliac or femoral or popliteal or femoro* or fempop* or crural) near/3 (obstruct* or occlus*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>326</P>
</TD>
</TR>
<TR>
<TD>
<P>#43</P>
</TD>
<TD>
<P>((bypass or graft) near/3 (*occlus* or steno* or restenos* or obstuct* or lesio* or block* or obliter*))</P>
</TD>
<TD ALIGN="RIGHT">
<P>887</P>
</TD>
</TR>
<TR>
<TD>
<P>#44</P>
</TD>
<TD>
<P>#14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43</P>
</TD>
<TD ALIGN="RIGHT">
<P>39771</P>
</TD>
</TR>
<TR>
<TD>
<P>#45</P>
</TD>
<TD>
<P>#13 and #44 in Trials</P>
</TD>
<TD ALIGN="RIGHT">
<P>1996</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;4 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;5 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;5 studies included in previous version of review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;No new studies included&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 records assessed by authors for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1988 records screened by TSC&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1988 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;1996 records identifiedfrom CENTRAL&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;8 records identified from Specialised Register&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1980 records not relevant&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1 record excluded, with reasons&lt;/p&gt;&lt;p&gt;7 further records deemed not relevant&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>